NCT02783690已完成2 期
A Randomized Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 88
- 试验地点
- 2
- 主要终点
- Complication Rate
研究概览
简要总结
This is a randomized controlled trial to determine the safety of 15 fraction vs 25 fraction pencil beam scanning proton radiotherapy after mastectomy in patients requiring regional nodal irradiation. Proton therapy is recognized as a standard option for the delivery of radiotherapy for breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Histologic confirmation of breast cancer resected by mastectomy with or without immediate reconstruction and chest wall and regional nodal irradiation planned.
- •pStage T1-T4N0-N3M0 or ypStage T0-4N0-N3M0 Note: The axilla must be staged by sentinel node biopsy alone, sentinel node biopsy followed by axillary node dissection, or axillary lymph node dissection alone
- •ECOG Performance Status (PS) 0 to
- •(Appendix I).
- •Negative pregnancy test done ≤7 days prior to registration, for women of childbearing potential only.
- •Radiotherapy must begin within 12 weeks of last surgery (breast or axilla) or last chemotherapy.
- •Note: Breast implants and expanders allowed
- •Able to and provides IRB approved study specific written informed consent
- •Ability to complete questionnaire (s) by themselves or with assistance
- •Able to complete all mandatory tests listed in section 4.0
- •Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- •Willing to provide tissue and blood samples for correlative research purposes.
- •Rochester and Arizona patients: Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136
- •Rochester patients: Willing to sign consent onto Evaluation of cardiac function in patients undergoing proton beam or photon radiotherapy, IRB number 15-007443
排除标准
- •Medical contraindication to receipt of radiotherapy.
- •Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent.
- •Active systemic lupus or scleroderma.
- •Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception
- •Prior receipt of ipsilateral breast or chest wall radiation that would result in significant overlap of radiation therapy fields. Prior contralateral radiotherapy for breast cancer is allowed.
- •Positive margins after definitive surgery
- •History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior study entry
- •Inflammatory breast cancer
- •Recurrent Breast Cancer
- •Boosts to the chest wall after mastectomy. Nodal boosts are allowed.
研究组 & 干预措施
Conventional Fractionation
No Intervention
50.0 Gy (RBE) in 25 daily fractions
Hypofractionation
Experimental
40 Gy (RBE) in 15 daily fractions
干预措施: Hypofractionation (Radiation)
结局指标
主要结局
Complication Rate
时间窗: 24 months
Will be defined as the percentage of women randomized who develop one or more of the following events: grade 3 or higher late adverse events; unplanned surgical intervention (not including planned serial fat grafting) in patients who undergo mastectomy with reconstruction.
次要结局
- Cosmesis(baseline, 2 years, and 5 years)
- Incidence of Acute Adverse Events(5 years)
- Incidence of Late Adverse Events(5 years)
- Reconstruction Failure(5 years)
- Quality of Life - Breast Cancer Outcomes(5 years)
- Cosmesis(baseline, 2 years, and 5 years)
- Ipsilateral Breast Tumor Recurrence (IBTR) Incidence(5 years)
- Distant Recurrence Incidence(5 years)
- Regional Recurrence Incidence(5 years)
- Disease-free Survival (DFS) at 3 Years(3 years post radiotherapy, up to 38 months)
- Overall Survival (OS) at 3 Years(3 years post radiotherapy, up to 38 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Ongoing 2b/3a inhibition In Myocardial infarction Evaluation.NL-OMON20108950
撤回
4 期
RCT of Epinephrine (None, 100mcg, and 200mcg) in a Hyperbaric Bupivacaine, Fentanyl and Morphine Spinal in C-sections.PregnancyCesarean SectionNCT03335293University of Florida
已完成
不适用
A Randomized Controlled Trial of the Usefulness of Double Balloon Enteroscopy and Single Balloon Enteroscopy for Small Intestinal DiseaseSmall Intestinal DiseaseJPRN-UMIN000000954Department of Gastroenterology,The University of Tokyo Hospital, Tokyo, Japan200
招募中
不适用
A Randomized Controlled Trial Testing the Effectiveness of an Indicated Depression Prevention Program ('Op Volle Kracht') Among Adolescent Girls with Elevated Depressive Symptoms.Adolescent girls, Depression, Prevention, Implicit Self-EsteemNL-OMON26120GGZ Oost-Brabant> GGZ Oost Brabant> Burgemeester de Kuyperlaan 5> 5461 AA Veghel> The Netherlands> Telefoon: 0413 - 84 68 00100
已完成
2 期
Treatment of Mild to Moderate Distal Subungual Onychomycosis of the ToenailOnychomycosisNCT00453271NanoBio Corporation443